Jake Holdreith and Ronald Schutz Named 2018 “Life Sciences Stars” by LMG Life Sciences

September 27, 2018

Robins Kaplan LLP is pleased to announce that Jake Holdreith and Ronald Schutz have been named “Life Science Stars” by LMG Life Sciences. Additionally, the firm has been recommended as a top Hatch-Waxman patent litigation firm for generic pharmaceutical companies.

Holdreith leads the firm’s Health and Life Sciences Industry Group. “Jake is not just a lawyer, he is an advisor,” noted one client in LMG’s analysis of the award. “He has a knack for understanding not only the legal ramifications of litigation strategy, but also how they interplay with business strategy.”

Schutz is the managing partner of the New York office and a leading IP trial lawyer. His advocacy skills have been recognized by numerous organizations, including Chambers, Benchmark Litigation, Managing Intellectual Property, and The National Law Journal, among others.

This is the fifth year that Holdreith and Schutz have been recognized as “Life Science Stars.” Recipients were chosen based on nearly 1,000 interviews and surveys, including firm-wide surveys, interviews with individual attorneys and clients, and a review of public information.


Jake M. Holdreith

Partner

Managing Partner, Minneapolis Office
Member of Executive Board

Ronald J. Schutz

Partner

Immediate Past Chairman
Member of Executive Board

Related Publications

November 8, 2024
Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
David Martinez, Navin Ramalingam - Los Angeles & San Francisco Daily Journal
September 18, 2024
Astellas Pharma, Inc. v. Sandoz Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 9, 2024
Purdue Pharma L.P v. Accord Healthcare Inc.
GENERICally Speaking Hatch Waxman Bulletin
September 4, 2024
Exeltis USA, Inc. v. Lupin Ltd.
GENERICally Speaking Hatch Waxman Bulletin
August 28, 2024
Teva Branded Pharm. Products R&D, Inc. v. Deva Holding A.S.
GENERICally Speaking Hatch Waxman Bulletin
Back to Top